ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP23

The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient

Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, education, patient, Managed Care, quality of care, Scleroderma, Systemic

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Patient Perspectives

Session Type: Patient Perspectives

Session Time: 5:00PM-6:00PM

Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in pain and stiffness, I sought out help. I was then diagnosed with Systemic Diffuse Scleroderma. I developed Interstitial Lung disease, hypertension and heart complications almost immediately. My skin became hard and tight. My hands contracted inward causing fingertip ulcerations which led to self-amputations. My experience with doctors, more specifically specialists, was extremely limited. Coping with a disease that changes your entire life in the blink of an eye is difficult. The worst part was trying to find care.

Intervention: In 2016, I was asked by The Ann Steffens Scleroderma Foundation to participate in their Interprofessional Educational Event (IPE). The event was to introduce academic clinician students of various disciplines to Scleroderma by using patients as educators. Looking back, I realized the program they implemented was the concept I had been working to put in place. A structured care team willing to work together to gather information collectively and treat scleroderma’s symptoms, complications, and disease processes collaboratively. This new way of care became a game-changer for me allowing for earlier diagnosis, more effective and complete care, leading to an enhanced quality of life. As a result, my confidence increased allowing me to take an active role alongside multi-disciplined specialists. Whether it was a Rheumatologist, Cardiologist, Pulmonologist, etc., I was confident in a collaborative approach.

Maintenance: Disease-specific care is organized, attentive, and maintained through strong communication and active listening, along with the patient’s perspective and input. In 2019 I had a severe cardiac event and ended up needing an Implantable cardioverter defibrillator (ICD). This decision led to forming a team of specialty Surgeons and Anesthesiologists to handle unfamiliar skin, breathing capacity issues and difficulty with intubation. As time passed my symptoms were monitored closely by highly trained Scleroderma professionals. They provided continual communication through multi-doctor assessments offering a keen sense of security. As a result, I had complete confidence in my team, as I was an active participant.

Quality of Life: It took me five years to find a Scleroderma collaborative care team. Once I did, it felt like coming home and it changed the trajectory of my disease. Before that I felt lost and out of control, like my disease was overtaking my body. My care team allowed me to speak openly about my experiences. They gave me precise, structured, and highly monitored care which offered me a better understanding of my disease process. I learned to pay attention to my symptoms, however big or small. When you are diagnosed with scleroderma, you’re never really free from it. Medication doesn’t make it disappear. Finding my care team gave me hope that there is a way to gain back the life that scleroderma took from me. My journey albeit 21 years later is still in the making because of the collaborative care team approach.

Supporting image 2

Amy giving a keynote speech at The Ann Steffens Scleroderma Foundation’s Interprofessional Educational Event.


Disclosures: A. Gietzen, None; H. Bowen, None.

To cite this abstract in AMA style:

Gietzen A, Bowen H. The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-journey-to-collaborative-care-and-patient-centric-educational-opportunities-for-a-scleroderma-patient/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-journey-to-collaborative-care-and-patient-centric-educational-opportunities-for-a-scleroderma-patient/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology